Industry / Switzerland
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
Novartis And Bayer To Go Head To Head Following EU Extavia Approval
May 2008 | Industry NewsSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
Swiss drugmaker Novartis has obtained EU approval for its multiple sclerosis (MS) treatment Extavia (interferon beta-1b), which will result in a head-to-head battle with Bayer's identical competitor drug Betaferon. The drug is expected to be launched in the EU in the first half of